candesartan has been researched along with l 162313 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR | 1 |
| Hongo, S; Kanome, T; Miyazaki, A; Nishio, K; Takahashi, K; Watanabe, T | 1 |
1 review(s) available for candesartan and l 162313
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
1 other study(ies) available for candesartan and l 162313
| Article | Year |
|---|---|
Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II Type 1 receptor in human monocyte-macrophages.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Endocytosis; Foam Cells; Humans; Imidazoles; Macrophages; Male; Oligopeptides; Radioimmunoassay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Signal Transduction; Sterol O-Acyltransferase; Tetrazoles; Up-Regulation; Vasoconstrictor Agents; Vasodilator Agents | 2008 |